- Conditions
- Locally Advanced Bladder Urothelial Carcinoma, Metastatic Transitional Cell Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Carcinoma, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
- Interventions
- Sapanisertib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Pasadena, California • Sacramento, California + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 769–792
of 7,009
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Spinal Cord Injuries
- Interventions
- Variable-dose TTNS Protocol 5 x week, Fixed-dose TTNS Protocol, Variable-dose TTNS Protocol 2 x week
- Device
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Houston, Texas
- Conditions
- IgA Nephropathy (IgAN)
- Interventions
- Avacopan, Prednisone, Methylprednisolone (drug), Prednisolone
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Chronic Kidney Disease 5D, Chronic Kidney Disease Stage 5, Kidney Failure, Kidney Failure,Chronic, Renal Insufficiency Chronic, Chronic Kidney Disease Stage 4, Kidney Transplantation, Waiting List, Transplant Candidate, Exercise Theraphy
- Interventions
- Exercise Rehabilitation Program with Physical Activity Tracker, Active control
- Behavioral · Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Mesothelioma, Fumarate Hydratase (FH)-Deficient Tumors, Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST), Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors, Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations, Tumors Harboring Amplifications in the cMyc Gene
- Interventions
- CB-839, Pac-CB, CBE, CB-Erl, CBD, CB-Cabo
- Drug
- Lead sponsor
- Calithera Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 13
- States / cities
- San Francisco, California • Stanford, California • Sarasota, Florida + 7 more
- Conditions
- Epilepsy
- Interventions
- ezogabine/retigabine
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 4
- States / cities
- Bethesda, Maryland • Columbus, Ohio • Dallas, Texas + 1 more
- Conditions
- Thyroid Disease, Kidney Diseases, Chronic
- Interventions
- Levothyroxine Sodium, Placebo Oral Tablet
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma, Metastatic Pancreatic Cancer, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Endometrial Cancer, Metastatic Castration-resistant Prostate Cancer
- Interventions
- Ceralasertib, Olaparib, Durvalumab
- Drug
- Lead sponsor
- Rahul Aggarwal
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 3
- States / cities
- Duarte, California • San Francisco, California • Chicago, Illinois
- Conditions
- Type 1 Diabetes, Diabetic Kidney Disease, Diabetes Complications, Diabetic Nephropathies, Autoimmune Diabetes
- Interventions
- Aminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF), Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Chronic Kidney Disease, Diabetes
- Interventions
- CKD Awareness, Referrals, Education, and Support (CARES), Attention control
- Behavioral
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Diabetic Kidney Disease
- Interventions
- Montelukast
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Urinary Incontinence, Parkinson's Disease
- Interventions
- Exercise-based behavioral therapy
- Other
- Lead sponsor
- Atlanta VA Medical Center
- Federal
- Eligibility
- 50 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Anemia
- Interventions
- Peginesatide, Epoetin alfa
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Azusa, California + 20 more
- Conditions
- Renal Cancer, Kidney Cancer, Renal Cell Carcinoma, Inferior Vena Cava Thrombosis
- Interventions
- Axitinib, Pembrolizumab
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Highlands Ranch, Colorado • Lone Tree, Colorado
- Conditions
- Frequent Relapsing Nephrotic Syndrome, Steroid Dependent Nephrotic Syndrome
- Interventions
- Rituximab, MMF
- Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Pregnancy Toxemia, Hypertension, Proteinuria
- Interventions
- methyldopa, labetalol, nifedipine, clonidine
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pneumonia, Heart Failure, Cellulitis, Urinary Tract Infections
- Interventions
- Home hospitalization, Inpatient Hospitalization
- Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Cystinuria
- Interventions
- Bucillamine
- Drug
- Lead sponsor
- Revive Therapeutics, Ltd.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Boston, Massachusetts • New York, New York + 2 more
- Conditions
- Infections, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulation, Diabetes and Its Complications, End of Life/Desires Only Medical Management
- Interventions
- Home Hospital care, Traditional Hospital care
- Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Quincy, Illinois • Hazard, Kentucky
- Conditions
- Urinary Bladder, Overactive, Urinary Incontinence, Accidental Falls
- Interventions
- Pelvic Floor Muscle Training, Mirabegron, Trospium Chloride
- Behavioral · Drug
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 60 Years to 99 Years · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, NMIBC, Urothelial Carcinoma Bladder, Urothelial Carcinoma in Situ, Urothelial Carcinoma Recurrent, Urothelial Carcinoma of the Urinary Bladder, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer (NMIBC)
- Interventions
- UGN-501
- Biological
- Lead sponsor
- UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 15
- States / cities
- Queen Creek, Arizona • Bakersfield, California • Murrieta, California + 12 more
- Conditions
- Cancer
- Interventions
- Fentanyl sublingual spray, Placebo
- Drug
- Lead sponsor
- INSYS Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Chandler, Arizona
- Conditions
- Urothelial Carcinoma, Ureteral Neoplasms, Ureter Cancer, Neoplasm, Ureteral, Cancer of the Ureter
- Interventions
- TRC105
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Renal Cell Carcinoma
- Interventions
- Everolimus, GDC-0980
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 8
- States / cities
- Fort Myers, Florida • St. Petersburg, Florida • Boston, Massachusetts + 5 more